FMC (FMC) Down 10.2% Since Last Earnings Report: Can It Rebound?

A month has gone by since the last earnings report for FMC (FMC). Shares have lost about 10.2% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is FMC due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.FMC’s Q3 Earnings Increase, Sales Decline on Lower PricesFMC reported a loss of $4.52 per share for third-quarter 2025. This compares unfavorably to earnings of 52 cents in the year-ago quarter.Barring one-time items, adjusted earnings per share were 89 cents, up from 69 cents reported a year ago.Revenues were $542 million in the quarter, down around 49% from the year-ago quarter’s levels. Excluding India, revenues were $961 million, down 10%.Third-quarter revenues decreased primarily due to one-time commercial actions taken in India to position the business for sale. Excluding that, third-quarter revenues still witnessed a decline of 10% from the prior-year quarter due to a 6% decrease in price from the decline linked to price reductions in specific "cost-plus" contracts with certain diamide partners, reflecting lower manufacturing costs and the other half stemmed from competitive pressure. The volumes in the core portfolio also decreased due to increased competition.Regional Sales PerformanceIn North America, sales increased 4% year over year to $244 million in the quarter. Sales in North America increased as a result of price gains in branded products and higher volume, including Adastrio fungicide based on fluindapyr. It topped the consensus estimate of $225 million.Latin American sales saw an 8% year-over-year decrease to $463 million in the reported quarter. Sales in Latin America suffered from increased pressure from generics, leading to lower volume and price decline of branded products. It missed the consensus estimate of $516 million.In Asia, excluding India, revenues declined 47% from the previous year to $99 million. Sales declined due to lower pricing, the removal of India and reduced volumes. It missed the consensus estimate of $153 million.EMEA experienced an 11% year-over-year sales increase to $155 million in the reported quarter. The growth was fueled by significant volume increases, especially in the growth portfolio from branded Cyazypyr offerings. The successful launch of Isoflex in Great Britain also drove sales. It lagged the consensus estimate of $158 million.FinancialsThe company had cash and cash equivalents of $497.7 million at the end of the quarter. Long-term debt was roughly $3.27 billion.Q4 GuidanceFMC expects fourth-quarter revenues (excluding India) to range between $1.12 billion and $1.22 billion, implying a 4% decline at the midpoint compared to 2024. Adjusted EBITDA is forecasted between $265 million and $305 million, indicating a 16% decline at the midpoint. Adjusted earnings per share are projected to be $1.14 to $1.36, indicating a 30% year-over-year decrease at the midpoint.How Have Estimates Been Moving Since Then?Since the earnings release, investors have witnessed a downward trend in estimates review.The consensus estimate has shifted -27.57% due to these changes.VGM ScoresAt this time, FMC has a poor Growth Score of F, however its Momentum Score is doing a bit better with a D. Charting a somewhat similar path, the stock has a score of C on the value side, putting it in the middle 20% for value investors.Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.OutlookEstimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise FMC has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.Radical New Technology Could Hand Investors Huge GainsQuantum Computing is the next technological revolution, and it could be even more advanced than AI.While some believed the technology was years away, it is already present and moving fast. Large hyperscalers, such as Microsoft, Google, Amazon, Oracle, and even Meta and Tesla, are scrambling to integrate quantum computing into their infrastructure.Senior Stock Strategist Kevin Cook reveals 7 carefully selected stocks poised to dominate the quantum computing landscape in his report, Beyond AI: The Quantum Leap in Computing Power.Kevin was among the early experts who recognized NVIDIA's enormous potential back in 2016. Now, he has keyed in on what could be "the next big thing" in quantum computing supremacy. Today, you have a rare chance to position your portfolio at the forefront of this opportunity.See Top Quantum Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report FMC Corporation (FMC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks